[{"orgOrder":0,"company":"Porton Biopharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Porton Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Solution","sponsorNew":"Porton Biopharma \/ Clinigen","highestDevelopmentStatusID":"12","companyTruncated":"Porton Biopharma \/ Clinigen"}]

Find Clinical Drug Pipeline Developments & Deals by Porton Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Under the terms of the agreement, Clinigen will distribute Erwinase®/ Erwinaze®, the Porton's life-saving treatment for acute lymphoblastic leukaemia.

Brand Name : Undisclosed

Molecule Type : Large molecule

Upfront Cash : Undisclosed

April 16, 2020

Lead Product(s) : Asparaginase

Therapeutic Area : Oncology

Highest Development Status : Approved

Sponsor : Clinigen Group

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank